Osteonecrosis of the jaw associated with ustekinumab in the treatment of Crohn's disease
MRONJ is a well-known side effect of antiresorptive and antiangiogenic drug treatment. Crohn's disease involves pro-inflammatory interleukins IL-12 and IL-23. Ustekinumab is a targeted therapy antagonist of the p40 subunit of IL-12 and -23 indicated in the treatment of immune-mediated inflammatory d...
محفوظ في:
| المؤلفون الرئيسيون: | , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Elsevier
2024-10-01
|
| سلاسل: | Heliyon |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.sciencedirect.com/science/article/pii/S2405844024145975 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|